University of Virginia Health System
Charlottesville, Virginia, 22908, United States
Location status: Recruiting
Location contact
Mike Shim, MD
PRINCIPAL_INVESTIGATOR
Roselove Nunoo-Asare, RT
CONTACT
Sarah Struchen, RN
CONTACT
NCT Number: NCT03331302
Hyper polarized Xenon-129 MRI will be directly compared to a radioactive Xe-133 scintigraphy to detect defects in lung ventilation from airflow limitation. This study is conducted as a pilot study with intention to conduct a larger clinical trial.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 1 / Phase 2
Charlottesville, Virginia, 22908, United States
Location status: Recruiting
Mike Shim, MD
PRINCIPAL_INVESTIGATOR
Roselove Nunoo-Asare, RT
CONTACT
Sarah Struchen, RN
CONTACT
Hyperpolarized Xenon-129 MRI has been developed by a number of techniques for imaging the lung that provide information about various aspects of lung function and structure. The main objective of this pilot study is to test and optimize the imaging parameters for a future industry sponsored clinical trial. The goal of the future trial is to determine the concordance between hyperpolarized xenon-129 ventilation MR imaging and nuclear medicine ventilation imaging (Gold Standard). In this study we will test the imaging parameters and techniques. We will directly compare human ventilation lung images in subjects with COPD, using nuclear medicine ventilation imaging with Xenon-133 gas scintigraphy versus hyperpolarized xenon-129 gas MRI. Our hypothesis is that current Xe-133 scintigraphy, which uses a radioactive gas (Xe-133) and produces a projection image of the lungs with relatively poor resolution, will not be able to detect small lung ventilation obstructions, which can be detected using hyperpolarized Xe-129 gas MRI.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
MRI ventilation scan of the lung with inhaled contrast agent (hyperpolarized Xenon-129)
Other names: Polarean Pilot study
Radioactive ventilation scintigraphy of the lung with inhaled radioactive contrast agent (Xenon-133)
Other names: Pilot study
Time frame: 12 months
Compare the quality of the imaging between hyper polarized xenon-129 and radioactive xenon-133
Contact information is provided by the study sponsor or research team.
Roselove Nunoo-Asare, RT
CONTACT
Sarah Struchen, RN
CONTACT
University of Virginia
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07073950
Chronic Disease, Chronic Obstructive Pulmonary Disease
Ahrensburg, Germany
View Trial DetailsNCT07512687
Chronic Disease, Chronic Obstructive Pulmonary Disease
Buffalo, New York, United States
View Trial DetailsNCT06862206
Chronic Disease, Chronic Obstructive Pulmonary Disease
Anhui, China
View Trial DetailsNCT06390345
Apnea, Body Weight
Boise, Idaho, United States
View Trial Details